Don’t be fooled, weight loss drug Ozempic and Wegovy can be devastating, serious side effects study shows! Be warend! Like Jenny Craig & Weight Watchers etc., you are sold a bag of deceit! Pancreas

Weight-loss drugs (originally diabetic drugs) like Ozempic and Wegovy come with the risk of serious gastrointestinal issues, including inflammation in the pancreas.

https://jamanetwork.com/journals/jama/fullarticle/2810542

‘There’s been a surge in demand for a class of diabetes drugs that are now popular for their serendipitous byproduct: weight loss.

Alexander COVID News-Dr. Paul Elias Alexander’s Newsletter is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

The drugs belong to a class called GLP-1 agonists and include semaglutide, the main ingredient in Ozempic, Wegovy, and Rybelsus; tirzepatide, which is found in Mounjaro; and liraglutide, used in Victoza and Saxenda. While effective in helping people with diabetes to lose about 15% of their body weight, these drugs are also linked to some risk of gastrointestinal side effects, including inflammation in the pancreas and obstructions of the digestive system.
[time-brightcove not-tgx=”true”]
But how common are these risks in people who don’t have diabetes, and are increasingly taking the drugs to lose weight? On Sept. 28, the U.S. Food and Drug Administration (FDA) asked manufacturers of the semaglutide drugs to include a warning in the medication label about the possible risk of intestinal blockage, after receiving 8,500 reports of the condition from both diabetic and non-diabetic users.
Now, in a research letter published in JAMA, scientists at the University of British Columbia provide additional data on the magnitude of those risks for people taking them purely for weight loss. They report that among 4,700 people without diabetes taking some form of GLP-1 and 650 people taking an older, different combination of weight loss drugs…
those taking GLP-1s had a nine times greater risk of pancreatitis and four times higher risk of both obstructed bowels and gastroparesis, which is a slower emptying of the stomach into the intestines.’

…cohort included 4144 liraglutide, 613 semaglutide, and 654 bupropion-naltrexone users. Incidence rates for the 4 outcomes were elevated among GLP-1 agonists compared with bupropion-naltrexone users (Table 1). For example, incidence of biliary disease (per 1000 person-years) was 11.7 for semaglutide, 18.6 for liraglutide, and 12.6 for bupropion-naltrexone and 4.6, 7.9, and 1.0, respectively, for pancreatitis.
Use of GLP-1 agonists compared with bupropion-naltrexone was associated with increased risk of pancreatitis (adjusted HR, 9.09 [95% CI, 1.25-66.00]), bowel obstruction (HR, 4.22 [95% CI, 1.02-17.40]), and gastroparesis (HR, 3.67 [95% CI, 1.15-11.90) but not biliary disease (HR, 1.50 [95% CI, 0.89-2.53]). Exclusion of hyperlipidemia from the analysis did not change the results (Table 2). Inclusion of GLP-1 agonists regardless of history of obesity reduced HRs and narrowed CIs but did not change the significance of the results (Table 2). E-value HRs did not suggest potential confounding by BMI.’
‘Additional studies are also needed to better understand why GLP-1 drugs have such adverse effects on the stomach and intestines. Some early work in both people with and without diabetes suggests that the medications slow the normal motion of the stomach and intestines, possibly even stunning the nervous system into inaction.’

Alexander COVID News-Dr. Paul Elias Alexander’s Newsletter is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

Go to Dr Alexancer on Substack
Author: Dr. Paul Alexander